Open in interactive viewer → charts, metric popovers & call review

Dyadic's First Real Revenue Quarter Was Also Its Quietest Surrender

The long-promised commercial transition arrived at $449,000 — and management finally stopped pretending the ramp was imminent
DYAI · Earnings Call · 2026-11-12

The $449,000 Quarter

Dyadic International reported third-quarter 2026 revenue of roughly $449,000, down 61% from about $1.165 million a year earlier. CFO Ping Rawson broke it down: $162,000 of research and development revenue, $276,000 of grant revenue, $10,000 of license fees. Add them up and you have essentially the whole quarter. Which is the story. Because the call opened with President and COO Joe Hazelton announcing that “Dyadic recorded its first direct commercial protein product sales, primarily involving recombinant transferrin and DNase I.” — Joseph Hazelton, President and COO · 2026-11-12 The first product revenue of this kind in company history — and it does not appear as a line you can point to. Hazelton said so himself: those sales "are not yet financially material." The milestone is real and long-awaited. It is also, at current scale, economically indistinguishable from zero. He then set expectations before anyone else could: “Our direct commercial sales remain modest and customer qualification and adoption are taking longer than we originally anticipated.” — Joseph Hazelton, President and COO · 2026-11-12 For a company whose entire equity story for six quarters has been "we are transitioning from a development shop to a commercial business," that sentence is the quarter.

The Promise That Quietly Expired

Go back to the August 2025 call. A private investor asked when Dyadic crosses over to profitability. Hazelton answered: “The goal is that we're cash flow positive by the end of 2026, and then we start to see increased profitability in 2027 and beyond.” — Joseph P. Hazelton · 2025-08-13 That end-of-2026 date is now roughly seven weeks away. On this call nobody mentioned it. What they mentioned instead was about $6 million of cash, cash equivalents, restricted cash and investment-grade securities against net operating cash use of roughly $590,000 per month — arithmetic that lands you near the end of the runway — alongside a $2.9 million registered direct offering completed during the quarter. And then this, tucked into the strategic section rather than the financial one:

We continue to evaluate all options to maximize the value of our platforms and assets, including financing alternatives, strategic partnerships and other opportunities to strengthen our balance sheet.

Joseph Hazelton, President and COO · 2026-11-12
The balance sheet itself is worth a look. Liabilities to assets crossed 100%, up 16.9 points year over year, after climbing roughly 43 points across the last twelve months. Market value has compressed accordingly: price-to-revenue sits at 7.8x versus a June 2020 peak near 138x. The tape tells the same tale: the stock is down 69% over the last 90 trading days and 77.8% from its July peak of $1.47, and remains 96.8% below its 2020 high. There is a recurring rhythm worth naming. A year ago, the last question on the November 2025 call was again about the burn: “Can you comment on the burn and, yeah, how much ability you have to do what you need to?” — Tony Bowers, Analyst · 2025-11-12 Four quarters later the answer is structurally the same — a few million of cash in, a few million of cash out, and a partner payment landing in the fourth quarter to dress the year-end print. This year that payment is $225,000 from Inzymes, tied to its first commercial sale of Dapibus-produced camel chymosin in October, to be recognized in Q4. A one-time partner check in the final quarter is becoming a Dyadic habit rather than an accident.

What Is Genuinely New: The Vertical Integration

Strip out the noise and one thing on this call truly did change. The alpha lactalbumin program — long Dyadic's highest-priority food opportunity — now has an actual demand-side anchor. The expanded collaboration with BRIG BIO now includes Strive Nutrition, described as the end customer, a US brand whose FreeMilk products sit on Walmart and CVS shelves. Hazelton walked analysts through the structure: a supply agreement with an initial 10 tons ramping to 200 tons, contingent on hitting economic and self-affirmed GRAS thresholds. Analyst Dick Williams put a number on it — roughly $10 million to $16 million of annual business at 200 metric tons for that single product and customer. Hazelton declined guidance but did not disagree, framing Strive as one customer among several: “It could be another 200, 300, 400 metric tons to somebody else.” — Joseph Hazelton, President and COO · 2026-11-12 Follow-on proteins — lactoferrin, human alpha-lactalbumin, eventually casein — are the stated expansion path. That is a coherent, capital-light model in a category with real demand. It is also, by management's own admission, gated on yields, cost thresholds and regulatory sign-off that have not yet been met.

What Went Quiet

Two themes that dominated the last year of Dyadic calls have gone conspicuously silent. The first is cultured meat, which was the company's highest-momentum theme in the first half of 2026 and now barely surfaces — a passing reference in Q&A about cell culture applications and nothing more. That fade is a real signal about where management now believes the money is: dairy proteins and industrial enzymes, not meat. The second is capital. Hazelton has spent years positioning Dyadic as a commercialization story; this call repositioned it as a licensing story, with the phrase strategic partnership doing more work than any product launch. Mark Emalfarb was blunt about the pharmaceutical side — the Gates-funded RSV and malaria antibody work, where C1 hit 12.1 and 13.2 grams per liter with roughly 90% human-like glycosylation, and where Gates MRI is now funding animal studies directly, with data due in Q1 2027: “It's slower than everyone would like because we don't have the money just to push it on our own, and we're relying on third parties to do it.” — Mark Emalfarb, Unknown - likely Executive or Senior Management · 2026-11-12 Even the good news — antibody validation advancing — is someone else's capital and someone else's timetable. Notably, none of these themes echo the market's loud themes of the moment, which are dominated by AI data centers, tariff refunds and power demand; Dyadic is not riding any of those waves, which is its own form of isolation.

The Read

Nothing broke this quarter. What happened is subtler and more useful: management stopped pretending the ramp was imminent. The candor — Hazelton openly noting they make to demand because “we don't have the money to do that” — Joseph Hazelton, President and COO · 2026-11-12 — is unusual for a micro-cap and arguably the healthiest thing said on the call. But candor about a slow ramp, a negative-equity balance sheet, and a funding line that only extends months is not a thesis. It is a holding pattern, and R&D still eats nearly half of every revenue dollar at 48% of revenue. The Strive vertical integration is the one piece of genuinely new evidence that the platform can touch an end market at scale — and everything now depends on whether the next twelve months bring a bigger check (a strategic partner, a licensing deal) before the cash does not.